Cargando…
Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA)
PURPOSE: The purpose of this study was to validate a new prognostic model (GI-GPA) originally derived from a multi-center database (USA, Canada, Japan). PATIENTS AND METHODS: This retrospective study included 92 German and Norwegian patients treated with individualized approaches, always including b...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020357/ https://www.ncbi.nlm.nih.gov/pubmed/32054485 http://dx.doi.org/10.1186/s13014-020-1484-9 |
_version_ | 1783497728051904512 |
---|---|
author | Nieder, Carsten Hintz, Mandy Popp, Ilinca Bilger, Angelika Grosu, Anca L. |
author_facet | Nieder, Carsten Hintz, Mandy Popp, Ilinca Bilger, Angelika Grosu, Anca L. |
author_sort | Nieder, Carsten |
collection | PubMed |
description | PURPOSE: The purpose of this study was to validate a new prognostic model (GI-GPA) originally derived from a multi-center database (USA, Canada, Japan). PATIENTS AND METHODS: This retrospective study included 92 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status and other variables was collected. The GI-GPA score was calculated as described by Sperduto et al. RESULTS: Median survival was 4 months. The corresponding figures for the 4 different prognostic strata were 2.3, 4.4, 9.4 and 12.7 months, respectively (p = 0.0001). Patients whose management included surgical resection had longer median survival than those who were treated with other approaches (median 11.9 versus 3.0 months, p = 0.002). Comparable results were seen for additional systemic therapy (median 8.5 versus 3.5 months, p = 0.01). CONCLUSION: These results confirm the validity of the GI-GPA in an independent dataset from a different geographical region, despite the fact that overall survival was shorter in all prognostic strata, compared to Sperduto et al. Potential explanations include differences in molecular tumor characteristics and treatment selection, both brain metastases-directed and extracranially. Long-term survival beyond 5 years is possible in a small minority of patients. |
format | Online Article Text |
id | pubmed-7020357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70203572020-02-20 Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA) Nieder, Carsten Hintz, Mandy Popp, Ilinca Bilger, Angelika Grosu, Anca L. Radiat Oncol Research PURPOSE: The purpose of this study was to validate a new prognostic model (GI-GPA) originally derived from a multi-center database (USA, Canada, Japan). PATIENTS AND METHODS: This retrospective study included 92 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy. Information about age, extracranial spread, number of brain metastases, performance status and other variables was collected. The GI-GPA score was calculated as described by Sperduto et al. RESULTS: Median survival was 4 months. The corresponding figures for the 4 different prognostic strata were 2.3, 4.4, 9.4 and 12.7 months, respectively (p = 0.0001). Patients whose management included surgical resection had longer median survival than those who were treated with other approaches (median 11.9 versus 3.0 months, p = 0.002). Comparable results were seen for additional systemic therapy (median 8.5 versus 3.5 months, p = 0.01). CONCLUSION: These results confirm the validity of the GI-GPA in an independent dataset from a different geographical region, despite the fact that overall survival was shorter in all prognostic strata, compared to Sperduto et al. Potential explanations include differences in molecular tumor characteristics and treatment selection, both brain metastases-directed and extracranially. Long-term survival beyond 5 years is possible in a small minority of patients. BioMed Central 2020-02-13 /pmc/articles/PMC7020357/ /pubmed/32054485 http://dx.doi.org/10.1186/s13014-020-1484-9 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Nieder, Carsten Hintz, Mandy Popp, Ilinca Bilger, Angelika Grosu, Anca L. Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA) |
title | Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA) |
title_full | Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA) |
title_fullStr | Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA) |
title_full_unstemmed | Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA) |
title_short | Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA) |
title_sort | validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (gi-gpa) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020357/ https://www.ncbi.nlm.nih.gov/pubmed/32054485 http://dx.doi.org/10.1186/s13014-020-1484-9 |
work_keys_str_mv | AT niedercarsten validationofthegradedprognosticassessmentforgastrointestinalcancerswithbrainmetastasesgigpa AT hintzmandy validationofthegradedprognosticassessmentforgastrointestinalcancerswithbrainmetastasesgigpa AT poppilinca validationofthegradedprognosticassessmentforgastrointestinalcancerswithbrainmetastasesgigpa AT bilgerangelika validationofthegradedprognosticassessmentforgastrointestinalcancerswithbrainmetastasesgigpa AT grosuancal validationofthegradedprognosticassessmentforgastrointestinalcancerswithbrainmetastasesgigpa |